Koshiba Takaaki, Li Ying, Takemura Mami, Wu Yanling, Sakaguchi Shimon, Minato Nagahiro, Wood Kathryn J, Haga Hironori, Ueda Mikiko, Uemoto Shinji
Department of Transplantation and Immunology, Horizontal Medical Research Organization, Faculty of Medicine, Kyoto University, 54 Kawaramachi-Shogoin, Sakyo-ku, Kyoto city 606-8507, Japan.
Transpl Immunol. 2007 Feb;17(2):94-7. doi: 10.1016/j.trim.2006.10.004. Epub 2006 Nov 10.
In the setting of our pediatric living-donor liver transplantation (LDLT), 87 patients (15.0% of all the patients: significantly higher proportion, compared with those of other transplant centers) achieved complete withdrawal of immunosuppression, which is referred to as "operational tolerance". Immunosuppressants were completely discontinued for 54 patients as scheduled, and for 33 because of EBV infection or other complications. Immunological analyses of the peripheral blood derived from operationally tolerant patients demonstrated that non-deletional tolerance takes place in which potentially reactive T cells to donor-antigens remain physically in the immune repertoire, but specifically suppressed by certain mechanisms. Not only CD4(+)CD25(high+) T cells were increased in the proportion in the tolerant patients' peripheral lymphocytes and suppressed MLR specifically to the donor antigen, but also FOXP3 expressing cells were present within the tolerant liver. Thus, among several mechanisms accounting for non-deletional tolerance, Tregs are likely to involve at least in part in our tolerant patients. Vdelta1gammadeltaT cells, a subset of gammadeltaT cells, which otherwise reside mainly in the intestine, emerge into the peripheral blood during successful pregnancy but not abortive pregnancy. Since Vdelta1gammadeltaT cells produce massive IL-10, it is proposed that Vdelta1gammadeltaT cells induce fetomaternal tolerance by promoting Th2 immune deviation. Consistent with pregnancy, IL-10 producing Vdelta1gammadeltaT cells emerge into the blood of our tolerant patients. This may reflect a common feature between fetomaternal tolerance and transplant tolerance. We began protocol biopsy in post-LDLT patients who exhibit normal liver function from January 2003. Operationally tolerant patients, albeit showing normal liver function, exhibited decrease in size and increase in number of the bile duct and the fibrosis to a greater extent, compared with patients on maintenance immunosuppression. This warrants serial protocol biopsy before and after complete cessation of immunosuppression even in the presence of normal liver function.
在我们的小儿活体肝移植(LDLT)中,87例患者(占所有患者的15.0%:与其他移植中心相比比例显著更高)实现了免疫抑制的完全停用,即所谓的“临床耐受”。54例患者按计划完全停用了免疫抑制剂,33例则因EB病毒感染或其他并发症而停用。对临床耐受患者外周血的免疫学分析表明,发生了非删除性耐受,即对供体抗原具有潜在反应性的T细胞在免疫库中仍然存在,但通过某些机制被特异性抑制。不仅耐受患者外周淋巴细胞中CD4(+)CD25(高+)T细胞的比例增加,且对供体抗原特异性抑制了混合淋巴细胞反应(MLR),而且耐受肝脏中存在表达FOXP3的细胞。因此,在几种导致非删除性耐受的机制中,调节性T细胞(Tregs)可能至少部分参与了我们的耐受患者。Vδ1γδT细胞是γδT细胞的一个亚群,通常主要存在于肠道中,在成功妊娠而非流产妊娠期间会进入外周血。由于Vδ1γδT细胞产生大量白细胞介素-10(IL-10),因此有人提出Vδ1γδT细胞通过促进Th2免疫偏移诱导母胎耐受。与妊娠一致,产生IL-10的Vδ1γδT细胞出现在我们耐受患者的血液中。这可能反映了母胎耐受和移植耐受之间的共同特征。自2003年1月起,我们开始对肝功能正常的LDLT术后患者进行方案活检。临床耐受患者尽管肝功能正常,但与维持免疫抑制的患者相比,胆管尺寸减小、数量增加以及纤维化程度增加更为明显。这表明即使肝功能正常,在免疫抑制完全停止前后也需要进行系列方案活检。